HighCape Partners

Modifi Biosciences is a leader in direct DNA modification and the development of novel cancer therapeutics. The company's strategy for combating cancer centers around modifying tumor DNA in a way that renders cancer cells irreparable while preserving the integrity of healthy cells. This unique approach empowers researchers to disrupt traditional oncology drug development methods.

Elutia is a commercial-stage regenerative medicine company dedicated to developing innovative products aimed at enhancing patient outcomes during surgical procedures, particularly for those receiving implantable medical devices. The company focuses on several key areas, including Device Protection, Women's Health, and Cardiovascular health, with the Women's Health segment generating the highest revenue. Utilizing proprietary tissue processing platforms, Elutia has created a range of advanced regenerative medical products that closely resemble natural biological materials. These products are designed to address unmet clinical needs by promoting healthy tissue formation and minimizing complications commonly associated with medical device implants, such as scar tissue formation and capsular contraction.

Modifi Biosciences is a leader in direct DNA modification and the development of novel cancer therapeutics. The company's strategy for combating cancer centers around modifying tumor DNA in a way that renders cancer cells irreparable while preserving the integrity of healthy cells. This unique approach empowers researchers to disrupt traditional oncology drug development methods.

Wellinks, Inc., based in New Haven, Connecticut, specializes in wearable health technology aimed at improving clinical outcomes. Initially founded as 109 Design LLC in 2014, the company develops innovative devices for managing conditions such as scoliosis and chronic obstructive pulmonary disease (COPD). Wellinks offers a smart strap that enables patients, parents, and healthcare providers to monitor the duration and fit of scoliosis braces, thereby preventing the need for surgeries. The technology provides real-time data and feedback, empowering users to make informed decisions about their treatment. Additionally, Wellinks focuses on individualized care for COPD patients, offering digital health systems that support remote monitoring and management of respiratory conditions, enhancing patient engagement and health outcomes. The company operates as a subsidiary of Convexity Scientific Inc.

Cybrexa, Inc. is focused on developing innovative DNA repair inhibitors aimed at enhancing cancer therapeutics through the use of peptide-based technology that directly targets the tumor microenvironment. Established in 2016 and based in New Haven, Connecticut, the company leverages a unique tumor-localizing peptide technology developed at Yale University. This approach aims to revolutionize drug delivery by improving the therapeutic index, allowing for safer administration of higher doses of chemotherapy and radiotherapy. Cybrexa's pipeline includes a collection of small molecule inhibitors that can be combined with existing anticancer agents, thereby expanding treatment options for patients and addressing significant unmet medical needs in oncology. Through its research, Cybrexa seeks to improve patient outcomes and redefine the landscape of cancer treatment.

Alphina Therapeutics is a biotechnology company focused on developing innovative therapies for cancer patients by targeting NAD Metabolic Deficiencies (NMD). The company utilizes proprietary biomarkers and insights to create companion diagnostics that identify specific cancer patient subsets with NMD. By targeting multiple nodes in NAD synthesis pathways, Alphina aims to develop selective small molecules that can effectively treat tumors while minimizing impact on normal tissues. Their approach involves characterizing altered states of NAD metabolism, enabling the development of new drug classes tailored to address defects in NAD metabolism associated with cancer. The ultimate goal is to translate these advancements quickly into clinical applications for improved cancer treatment.

Flyp Nebulizer, the medical device is reinvented by Weblinks for respiratory care around the people who need it most. It works at ultrasonic speed to create a fine aerosol of medication. Flyp Nebulizer works quickly to deliver treatment within 7-minute average.

Wellinks, Inc., based in New Haven, Connecticut, specializes in wearable health technology aimed at improving clinical outcomes. Initially founded as 109 Design LLC in 2014, the company develops innovative devices for managing conditions such as scoliosis and chronic obstructive pulmonary disease (COPD). Wellinks offers a smart strap that enables patients, parents, and healthcare providers to monitor the duration and fit of scoliosis braces, thereby preventing the need for surgeries. The technology provides real-time data and feedback, empowering users to make informed decisions about their treatment. Additionally, Wellinks focuses on individualized care for COPD patients, offering digital health systems that support remote monitoring and management of respiratory conditions, enhancing patient engagement and health outcomes. The company operates as a subsidiary of Convexity Scientific Inc.

Cybrexa, Inc. is focused on developing innovative DNA repair inhibitors aimed at enhancing cancer therapeutics through the use of peptide-based technology that directly targets the tumor microenvironment. Established in 2016 and based in New Haven, Connecticut, the company leverages a unique tumor-localizing peptide technology developed at Yale University. This approach aims to revolutionize drug delivery by improving the therapeutic index, allowing for safer administration of higher doses of chemotherapy and radiotherapy. Cybrexa's pipeline includes a collection of small molecule inhibitors that can be combined with existing anticancer agents, thereby expanding treatment options for patients and addressing significant unmet medical needs in oncology. Through its research, Cybrexa seeks to improve patient outcomes and redefine the landscape of cancer treatment.

Zipline Medical, Inc. is a healthcare company specializing in the development and commercialization of non-invasive skin closure solutions. Founded in 2009 and based in Campbell, California, the company focuses on its innovative PRELOC™ technology platform, which provides uniform closure forces while minimizing tension that can lead to scarring. The flagship product, Zip Surgical Skin Closure, is applicable across a range of medical specialties, including cardiology, orthopedics, dermatology, and emergency medicine. The technology aims to combine the speed of staples with the cosmetic advantages of sutures, addressing the clinical need for rapid and effective skin closure while reducing the risk of surgical site infections. By eliminating skin punctures and decreasing the risk of needlestick injuries, Zipline Medical enhances surgical outcomes and patient care in various surgical procedures. The company operates as a subsidiary of Stryker Corporation.

Cheetah Medical, Inc. is a medical technology company specializing in the development and commercialization of non-invasive solutions for monitoring cardiac output and hemodynamics. Its flagship product, the CHEETAH NICOM system, is a non-invasive cardiac output monitor that aids in clinical applications such as fluid optimization, hemodynamic diagnosis, and drug titration. The system provides valuable insights into conditions like hypovolemic shock, septic shock, and acute renal failure, among others. CE marked and FDA cleared, the CHEETAH NICOM is recognized for its equivalence to invasive monitoring systems. Cheetah Medical distributes its products to medical centers across numerous countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, Cheetah Medical also maintains offices in Vancouver, Washington, Tel Aviv, Israel, and the United Kingdom, and operates as a subsidiary of Baxter International Inc. The company remains dedicated to research and development, collaborating closely with clinicians to enhance patient outcomes.

Cybrexa, Inc. is focused on developing innovative DNA repair inhibitors aimed at enhancing cancer therapeutics through the use of peptide-based technology that directly targets the tumor microenvironment. Established in 2016 and based in New Haven, Connecticut, the company leverages a unique tumor-localizing peptide technology developed at Yale University. This approach aims to revolutionize drug delivery by improving the therapeutic index, allowing for safer administration of higher doses of chemotherapy and radiotherapy. Cybrexa's pipeline includes a collection of small molecule inhibitors that can be combined with existing anticancer agents, thereby expanding treatment options for patients and addressing significant unmet medical needs in oncology. Through its research, Cybrexa seeks to improve patient outcomes and redefine the landscape of cancer treatment.

Elutia is a commercial-stage regenerative medicine company dedicated to developing innovative products aimed at enhancing patient outcomes during surgical procedures, particularly for those receiving implantable medical devices. The company focuses on several key areas, including Device Protection, Women's Health, and Cardiovascular health, with the Women's Health segment generating the highest revenue. Utilizing proprietary tissue processing platforms, Elutia has created a range of advanced regenerative medical products that closely resemble natural biological materials. These products are designed to address unmet clinical needs by promoting healthy tissue formation and minimizing complications commonly associated with medical device implants, such as scar tissue formation and capsular contraction.

Zipline Medical, Inc. is a healthcare company specializing in the development and commercialization of non-invasive skin closure solutions. Founded in 2009 and based in Campbell, California, the company focuses on its innovative PRELOC™ technology platform, which provides uniform closure forces while minimizing tension that can lead to scarring. The flagship product, Zip Surgical Skin Closure, is applicable across a range of medical specialties, including cardiology, orthopedics, dermatology, and emergency medicine. The technology aims to combine the speed of staples with the cosmetic advantages of sutures, addressing the clinical need for rapid and effective skin closure while reducing the risk of surgical site infections. By eliminating skin punctures and decreasing the risk of needlestick injuries, Zipline Medical enhances surgical outcomes and patient care in various surgical procedures. The company operates as a subsidiary of Stryker Corporation.

Cheetah Medical, Inc. is a medical technology company specializing in the development and commercialization of non-invasive solutions for monitoring cardiac output and hemodynamics. Its flagship product, the CHEETAH NICOM system, is a non-invasive cardiac output monitor that aids in clinical applications such as fluid optimization, hemodynamic diagnosis, and drug titration. The system provides valuable insights into conditions like hypovolemic shock, septic shock, and acute renal failure, among others. CE marked and FDA cleared, the CHEETAH NICOM is recognized for its equivalence to invasive monitoring systems. Cheetah Medical distributes its products to medical centers across numerous countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, Cheetah Medical also maintains offices in Vancouver, Washington, Tel Aviv, Israel, and the United Kingdom, and operates as a subsidiary of Baxter International Inc. The company remains dedicated to research and development, collaborating closely with clinicians to enhance patient outcomes.